Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
LONDON, UK – Heart attack patients without heart failure derive no benefit from the addition of mineralocortoid receptor antagonists (MRA), to standard therapy, results of the ALBATROSS study show.
EMBARGO :30 August 2015 at 08:00 BST
The Hot Line findings, reported at ESC Congress 2015, “do not warrant the extension of MRA use” to such patients, said the study’s principal investigator Gilles Montalescot, MD, PhD.
MRAs, also known as aldosterone antagonists, inhibit sodium retention and excretion of potassium and magnesium, and therefore “there is an indication for MRA therapy in MI patients with heart failure,” explained Professor Montalescot, from the Institut de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpêtriėre, in Paris, France.
“Our results suggest that heart failure is the main factor for the favorable effect of MRAs previously observed in MI patients. In MI patients without heart failure we observed no benefit. We suggest to respect the current indication driven by heart failure.”But there is a silver lining to the ALBATROSS findings, which do suggest “a potential mortality benefit” of MRA treatment among a specific group of patients who have ST-segment elevation myocardial infarction (STEMI), although this result “must be interpreted with great caution,” warned Professor Montalescot.
“It is an intriguing, hypothesis-generating finding which needs to be examined further in adequately-sized trials specifically dedicated to STEMI patients,” he said.
While the MRAs spironolactone and eplerenone have both been shown to reduce mortality in heart attack patients with congestive heart failure, very little is known about this treatment in the absence of heart failure – the more common scenario among patients who are hospitalised for myocardial infarction (MI).
Therefore, ALBATROSS (which stands for Aldosterone Lethal effects Blockade in Acute myocardial infarction Treated with or without Reperfusion to improve Outcome and Survival at Six months follow-up) investigated the effects of prolonged MRA therapy initiated early after the onset of MI in a broad population, 92% of whom presented without heart failure.The study included 1622 patients randomly assigned to standard therapy alone (n=801) or with the addition of MRA therapy (n=802).The randomisation took place as early as possible, including in ambulances, to allow for early treatment.Standard therapy included in-hospital medications as well as procedures such as coronary angiography, percutaneous coronary intervention and coronary bypass grafting.The MRA regimen consisted of an intravenous bolus of potassium canrenoate (200 mg) followed by an initial 25mg of oral spironolactone within 12 to 24 hours, and then daily for 6 months. Spironolactone was not given if either potassium or creatinine concentrations were uncontrolled (> 5•5 mmol.L-1 and >220 µmol.L-1 respectively).
After a median follow-up of 118 days, the primary outcome - a composite of death, resuscitated cardiac arrest, significant ventricular arrhythmia, indication for an implantable defibrillator or new or worsening heart failure at 6-months - occurred at a similar rate in the treatment and control groups (11•8% and 12•2% respectively, hazard ratio [HR] 0•97).However, for the outcome of mortality alone, MRA reduced the odds of death in the subgroup of STEMI (n=1229, HR 0•20, 95% CI, 0.06 to 0.70), but not NSTEMI patients.
Caution in interpreting this finding is warranted since the study was not designed to specifically assess STEMI patients, said Professor Montalescot, but he added that a potential benefit of early MR therapy is plausible in STEMI patients, who are “a more homogeneous patient population with more acute and severe myocardial ischemia than NSTEMI”.The ALBATROSS study, which is the largest study of MRA therapy in MI patients without heart failure, also highlights the relative safety of the MRA regimen used. Adverse events were equally distributed between the two study groups and although rates of hyperkalemia (high plasma potassium) were more common in the MRA group than in the control group, they were lower than what has been previously reported, he concluded.
The study was funded by the French Ministry of Health and the Institute of Cardiometabolism And Nutrition (ICAN).DISCLOSURES: Dr. Montalescot reports receiving consulting fees from Acuitude, Amgen, AstraZeneca, Bayer, Berlin Chimie AG, Boehringer Ingelheim, Bristol-Myers Squibb, Brigham Women’s Hospital, Cardiovascular Research Foundation, CME resources, Conway, Daiichi-Sankyo, Eli-Lilly, Europa, Evidera, GLG, Hopitaux Universitaires Genève, Lead-Up, McKinsey & Company, Medcon International, Menarini, Medtronic, MSD, Pfizer, Sanofi-Aventis, Stentys, The Medicines Company, TIMI Study Group, Universitat Basel, WebMD, Williams & Connolly, Zoll Medical and grant support from ADIR, Amgen, AstraZeneca, Bristol-Myers Squibb, Celladon, Daiichi-Sankyo, Eli-Lilly, Fédération Française de Cardiologie, Gilead, ICAN, Janssen-Cilag, Pfizer, Recor, Sanofi-Aventis, Stentys
ESC Press OfficeFor background information or assistance, please contact the ESC Press Office.For independent comment on site or interviews, please contact the ESC spokesperson coordinator: +44 7785 467 947
About the European Society of CardiologyThe European Society of Cardiology (ESC) represents more than 90 000 cardiology professionals across Europe and worldwide. Its mission is to reduce the burden of cardiovascular disease in Europe. About ESC Congress 2015ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2015 takes place 29 August to 2 September at ExCel London in London, UK. Access the scientific programme. More information is available from the ESC Press Office at firstname.lastname@example.org.To access all the scientific resources from the sessions during the congress, visit ESC Congress 365. This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2015. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.
© 2017 European Society of Cardiology. All rights reserved